General and comparative efficacy and effectiveness of antidepressants in the acute treatment of depressive disorders: a report by the WPA section of pharmacopsychiatry

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Atypical depression: a variant of bipolar II or a bridge between unipolar and bipolar II?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The DSM-IV and ICD-10 categories of recurrent [major] depressive and bipolar II disorders: Evidence that they lie on a dimensional spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Continuous distribution of atypical depressive symptoms between major depressive and bipolar II disorders: dose-response relationship with bipolar family history

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Acceleration and augmentation strategies for treating bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Treatment algorithms in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression--lack of manic induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Contemporary management of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The Zurich Study--a prospective epidemiological study of depressive, neurotic and psychosomatic syndromes. IV. Recurrent and nonrecurrent brief depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Melancholia and atypical depression in the Zurich study: epidemiology, clinical characteristics, course, comorbidity and personality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Diagnostic conversion from depression to bipolar disorders: results of a long-term prospective study of hospital admissions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Sleep and circadian rhythms in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The influence of concomitant antidepressant medication on safety, tolerability and clinical effectiveness of electroconvulsive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Recent progress in pharmacological and non-pharmacological treatment options of major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Evaluation of a salivary based combined dexamethasone/CRH test in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Placebo-controlled studies in depression: necessary, ethical and feasible

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Efficacy of couple therapy as a treatment for depression: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Early reduction in prefrontal theta QEEG cordance value predicts response to venlafaxine treatment in patients with resistant depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The role of venlafaxine and duloxetine in the treatment of depression with decremental changes in somatic symptoms of pain, chronic pain, and the pharmacokinetics and clinical considerations of duloxetine pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Double-blind, placebo-controlled trial of the use of lithium to augment antidepressant medication in continuation treatment of unipolar major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Lithium augmentation in treatment-resistant depression: meta-analysis of placebo-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Efficacy of an algorithm-guided treatment compared with treatment as usual: a randomized, controlled study of inpatients with depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The effect of venlafaxine compared with other antidepressants and placebo in the treatment of major depression: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthre

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Is the antidepressive effect of second-generation antidepressants a myth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Regression towards the mean

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Some examples of regression towards the mean

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Mirtazapine and paroxetine in major depression: a comparison of monotherapy versus their combination from treatment initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Combination of antidepressant medications from treatment initiation for major depressive disorder: a double-blind randomized study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Psychological interventions for major depression in primary care: a meta-analytic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The value of HMPAO SPECT in predicting treatment response to citalopram in patients with major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Committee for Medicinal Products for Human Use (CHMP) assessment on efficacy of antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Thyrotropin, but not a polymorphism in type II deiodinase, predicts response to paroxetine in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Treatment response in melancholia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Sertraline and/or interpersonal psychotherapy for patients with dysthymic disorder in primary care: 6-month comparison with longitudinal 2-year follow-up of effectiveness and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Association between response to lithium augmentation and the combined DEX/CRH test in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Efficacy and mechanisms of action of lithium augmentation in refractory major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A controlled evaluation of monthly maintenance interpersonal psychotherapy in late-life depression with varying levels of cognitive function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Adjustment disorder: epidemiology, diagnosis and treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Compelling or irrelevant? Using number needed to treat can help decide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The number needed to treat: a clinically useful measure of treatment effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The facets of melancholia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Commentary on STAR*D: a summary and UK perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Adding psychotherapy to pharmacotherapy in the treatment of depressive disorders in adults: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Are Psychological and Pharmacologic Interventions Equally Effective in the Treatment of Adult Depressive Disorders?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Morning fluoxetine plus evening mianserin versus morning fluoxetine plus evening placebo in the acute treatment of major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Divalproex in the treatment of bipolar depression: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Case report: excellent response to long-term higher dose single olanzapine in a case of recurrent brief depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A systematic review of research findings on the efficacy of interpersonal therapy for depressive disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The emerging role of melatonin agonists in the treatment of major depression: focus on agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Speed of action: the relative efficacy of short psychodynamic supportive psychotherapy and pharmacotherapy in the first 8 weeks of a treatment algorithm for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Atypical antipsychotics in bipolar disorder: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Cognitive therapy versus medication for depression: treatment outcomes and neural mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

To combine or not to combine? A literature review of antidepressant combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Summary measures of number needed to treat: how much clinical guidance do they provide in neuropathic pain?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Sustained administration of bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in the rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Diagnosis and definition of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Definition and epidemiology of treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The Problem of the Placebo Response in Clinical Trials for Psychiatric Disorders: Culprits, Possible Remedies, and a Novel Study Design Approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A Comparison of Mirtazapine and Nortriptyline Following Two Consecutive Failed Medication Treatments for Depressed Outpatients: A STAR*D Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Benefits from mianserin augmentation of fluoxetine in patients with major depression non-responders to fluoxetine alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

21 January 2018

Resurrecting melancholia

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Antidepressant drug effects and depression severity: a patient-level meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Design of clinical trials of antidepressants: should a placebo control arm be included?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Clinical practice. Bipolar disorder--a focus on depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Enhancement of serotonergic and noradrenergic neurotransmission in the rat hippocampus by sustained administration of bupropion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Antidepressants for bipolar depression: a systematic review of randomized, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Nortriptyline and gabapentin, alone and in combination for neuropathic pain: a double-blind, randomised controlled crossover trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Modelling placebo response in depression trials using a longitudinal model with informative dropout

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

ECNP consensus meeting. Bipolar depression. Nice, March 2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Lithium: updated human knowledge using an evidence-based approach: Part I: Clinical efficacy in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Trimipramine: Pharmacological reevaluation and comparison with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Difficult-to-treat depression: the role of contexts and comorbidities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of bipolar disorders. Part I: Treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

St. John's Wort. An option for the primary care treatment of depressive patients?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Antidepressant treatment in the primary care office: outcomes for adjustment disorder versus major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an update on psychotic depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Effects of pharmacotherapy and psychotherapy in depressed primary-care patients: a randomized, controlled trial including a patients' choice arm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Should combined pharmaco- and psychotherapy be offered to depressed patients? A qualitative review of randomized clinical trials from the 1990s

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Symptomatology of Therapy-Resistant Depressions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Sleep deprivation in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Treatment of depression with atypical features: a meta-analytic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Depression with atypical features in a sample of primary care outpatients: prevalence, specific characteristics and consequences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Does psychosocial functioning improve independent of depressive symptoms? A comparison of nefazodone, psychotherapy, and their combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Frontal EEG predictors of treatment outcome in major depressive disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The combined dexamethasone/CRH test as a potential surrogate marker in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Neuropathic pain treatment: a further step forward

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Lithium carbonate and imipramine in the prophylaxis of unipolar and bipolar II illness: a prospective, placebo-controlled comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Hypericum perforatum--a review of clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Efficacy of St. John's wort extract WS 5570 in acute treatment of mild depression: a reanalysis of data from controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Efficacy of the novel antidepressant agomelatine on the circadian rest-activity cycle and depressive and anxiety symptoms in patients with major depressive disorder: a randomized, double-blind comparison with sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Beyond the monoaminergic hypothesis: agomelatine, a new antidepressant with an innovative mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The effects of phototherapy in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Phototherapy in individuals with and without subsyndromal seasonal affective disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Phototherapy in subsyndromal seasonal affective disorder (S-SAD) and "diagnosed" controls.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Placebo-controlled trial of lithium augmentation of fluoxetine and lofepramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Rethinking depression and the actions of antidepressants: uncovering the links between the neural and behavioral elements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Relief of expressed suicidal intent by ECT: a consortium for research in ECT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Improving the prediction of treatment response in depression: integration of clinical, cognitive, psychophysiological, neuroimaging, and genetic measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Clinical value of early partial symptomatic improvement in the prediction of response and remission during short-term treatment trials in 3369 subjects with bipolar I or II depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Effectiveness of lamotrigine in bipolar disorder in a clinical setting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Predicting stable treatment response in patients with major depression treated with hypericum extract WS 5570/5572.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Contribution of allelic variations in transporters to the phenotype of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Rostral anterior cingulate cortex theta current density and response to antidepressants and placebo in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Current investigational drugs for major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A computerized decision support system for depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

New developments in psychosocial interventions for adults with unipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The Korean Medication Algorithm for Major Depressive Disorder (KMA-MDD): Report of the Korean Society of Depressive and Bipolar Disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The response to sertraline in men with chronic pelvic pain syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Biochemical aspects of therapy-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Phase-shifts of 24-h rhythms of hormonal release and body temperature following early evening administration of the melatonin agonist agomelatine in healthy older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

How to read and understand and use systematic reviews and meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Effectiveness of a quantitative electroencephalographic biomarker for predicting differential response or remission with escitalopram and bupropion in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in Major Depressive Disorder: results of the BRITE-MD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A double-blind comparison of moclobemide and doxepin in depressed general practice patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Patterns of early change and their relationship to outcome and follow-up among patients with major depressive disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Naturalistic outcomes of minor and subsyndromal depression in older primary care patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

One-year outcomes of minor and subsyndromal depression in older primary care patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The antidepressant debate continues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The Norwegian naturalistic treatment study of depression in general practice (NORDEP)-I: randomised double blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The functional impact of subsyndromal depressive symptoms in bipolar disorder: data from STEP-BD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Do antidepressants work? A commentary on "Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration" by Kirsch et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A regulatory Apologia--a review of placebo-controlled studies in regulatory submissions of new-generation antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Diagnostic guidelines for bipolar depression: a probabilistic approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Does adding psychotherapy to pharmacotherapy improve social functioning in the treatment of outpatient depression?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Evidence for beneficial effects of antidepressants on suicidality in depressive patients: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Isn't the efficacy of antidepressants clinically relevant? A critical comment on the results of the metaanalysis by Kirsch et al. 2008.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Antidepressants: controversies about their efficacy in depression, their effect on suicidality and their place in a complex psychiatric treatment approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Is evidence sufficient for evidence-based medicine?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Principle standards and problems regarding proof of efficacy in clinical psychopharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Do recent efficacy data on the drug treatment of acute bipolar depression support the position that drugs other than antidepressants are the treatment of choice? A conceptual review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Evidence-based medicine in psychopharmacotherapy: possibilities, problems and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Which antidepressants have demonstrated superior efficacy? A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Severe depression and antidepressants: focus on a pooled analysis of placebo-controlled studies on agomelatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Is the significant superiority of escitalopram compared with other antidepressants clinically relevant?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Novel methods to deal with publication biases: secondary analysis of antidepressant trials in the FDA trial registry database and related journal publications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Treatment of depression in the elderly: a review of the recent literature on the efficacy of single- versus dual-action antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Age may affect response to antidepressants with serotonergic and noradrenergic actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Comparison between the analysis of the loudness dependency of the auditory N1/P2 component with LORETA and dipole source analysis in the prediction of treatment response to the selective serotonin reuptake inhibitor citalopram in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Prediction of treatment response in major depression: integration of concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Escitalopram in the treatment of multisomatoform disorder: a double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Lithium reduces pathological aggression and suicidality: a mini-review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Double-blind, placebo-controlled comparison of imipramine and paroxetine in the treatment of bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Atypical depression: a comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Combined pharmacotherapy and psychological treatment for depression: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Defining melancholia: the primacy of psychomotor disturbance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Interpersonal psychotherapy for depression? The need to define its ecological niche

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Cognitive behavior therapy for depression? Choose horses for courses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

SSRIs as mood stabilizers for Bipolar II Disorder? A proof of concept study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Comparison of racemic ketamine and S-ketamine in treatment-resistant major depression: report of two cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The high prevalence of "soft" bipolar (II) features in atypical depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Recurrent brief depression revisited

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Recurrent brief depressive episodes. Epidemiology, clinical aspects, diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Prediction of clinical response to antidepressants in patients with depression: neurophysiology in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomised comparison.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Rate of switch in bipolar patients prospectively treated with second-generation antidepressants as augmentation to mood stabilizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Lithium carbonate and imipramine in prevention of affective episodes. A comparison in recurrent affective illness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Prediction of the response to citalopram and reboxetine in post-stroke depressed patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A comparison of paroxetine and amisulpride in the treatment of dysthymic disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Winter depression recurrence one year after cognitive-behavioral therapy, light therapy, or combination treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A randomized controlled trial of cognitive-behavioral therapy, light therapy, and their combination for seasonal affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

ECT in the treatment of the catatonic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Issues for DSM-V: seasonal affective disorder and seasonality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Research issues in the study of difficult-to-treat depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Depression, IV: STAR*D treatment trial for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Effect of concomitant pharmacotherapy on electroconvulsive therapy outcomes: short-term efficacy and adverse effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Sensitivity of the Montgomery Asberg Depression Rating Scale to response and its consequences for the assessment of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The antinociceptive properties of reboxetine in acute pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The combined dexamethasone/CRH Test (DEX/CRH test) and prediction of acute treatment response in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Do efficacy and effectiveness samples differ in antidepressant treatment outcome? An analysis of eligibility criteria in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Safety and tolerability of lamotrigine: results from 12 placebo-controlled clinical trials and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Evidence for the efficacy of duloxetine in treating mild, moderate, and severe depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

An international study of the relation between somatic symptoms and depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A double-blind, randomized trial of duloxetine versus placebo in the management of chronic low back pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A 12-week study comparing moclobemide and sertraline in the treatment of outpatients with atypical depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Treatment resistant depression: methodological overview and operational criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Catatonia in depression: prevalence, clinical correlates, and validation of a scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Onset of improvement under fluoxetine and moclobemide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Onset of action under antidepressant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Atypical depression: current status and relevance to melancholia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Suicidality as rare adverse event of antidepressant medication: report from the AMSP multicenter drug safety surveillance project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Pharmacological profile of antidepressants and related compounds at human monoamine transporters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Catatonia in psychiatric classification: a home of its own.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

STEP-BD and bipolar depression: what have we learned?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

MAOIs in the contemporary treatment of depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Can meta-analyses be trusted?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Dual monoamine modulation for improved treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Measurement-based care for refractory depression: a clinical decision support model for clinical research and practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Combined treatment with sulpiride and paroxetine for accelerated response in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Efficacy and tolerability of Hypericum extract STW 3-VI in patients with moderate depression: a double-blind, randomized, placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Genetic predictors of response to antidepressants in the GENDEP project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Pharmacotherapy of dysthymic and chronic depressive disorders: overview with focus on moclobemide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Placebo response in studies of major depression: variable, substantial, and growing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The antidepressant debate and the balanced placebo trial design: an ethical analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The psychological treatment of depression. Evidence for the efficacy of psychotherapy alone, in comparison with, and in combination with pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Chronotherapeutics (light and wake therapy) in affective disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Sleep deprivation in depression: what do we know, where do we go?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Rapid and sustained antidepressant response with sleep deprivation and chronotherapy in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Antidepressants and suicidal behaviour in unipolar depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Prediction of antidepressant response to milnacipran by norepinephrine transporter gene polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Mechanisms for the anti-nociceptive actions of the descending noradrenergic and serotonergic systems in the spinal cord

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Cortisol response in the combined dexamethasone/CRH test as predictor of relapse in patients with remitted depression. a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Lithium augmentation in depressive patients not responding to selective serotonin reuptake inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program

21 January 2018

2 references

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

21 January 2018

12 December 2020

A multivantaged behavioural method for measuring onset and sequence of the clinical actions of antidepressants

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Antidepressant effects of light in seasonal affective disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

The biological basis of an antidepressant response to sleep deprivation and relapse: review and hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Tranylcypromine Versus Venlafaxine Plus Mirtazapine Following Three Failed Antidepressant Medication Trials for Depression: A STAR*D Report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Bright light therapy in seasonal affective disorder – does it suffice?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

21 January 2018

Ranking antidepressants

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Efficacy and Safety of Lamotrigine as Add-On Treatment to Lithium in Bipolar Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Changes of clinical pattern in seasonal affective disorder (SAD) over time in a German-speaking sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Subdiagnostische Depressionen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00406-011-0259-6

Antidepressants versus placebo for depression in primary care

21 January 2018

1 reference

12 December 2020

[Elements for the effective treatment of patients with depressive disorders at the primary care level]

1 reference

12 December 2020

A 24-week study of 20 mg citalopram, 40 mg citalopram, and placebo in the prevention of relapse of major depression.

1 reference

12 December 2020

Moclobemide Versus Clomipramine in Depressed Patients in General Practice. A Randomized, Double-Blind, Parallel, Multicenter Study

1 reference

12 December 2020

Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression

1 reference

12 December 2020

Nonpharmacological, somatic treatments of depression: electroconvulsive therapy and novel brain stimulation modalities

1 reference

12 December 2020

Revisiting the effectiveness of standard antidepressants in bipolar disorder: are monoamine oxidase inhibitors superior?

1 reference

12 December 2020

[Problems of evidence-based medicine in psychopharmacotherapy: problems of evidence grading and of the evidence basis for complex clinical decision making]

1 reference

12 December 2020

Outcomes of 1014 naturalistically treated inpatients with major depressive episode

1 reference

12 December 2020

Can long-term treatment with antidepressant drugs worsen the course of depression?

1 reference

12 December 2020

Marital therapy for depression

1 reference

12 December 2020

Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study

1 reference

12 December 2020

Randomized Trial of Weekly, Twice-Monthly, and Monthly Interpersonal Psychotherapy as Maintenance Treatment for Women With Recurrent Depression

1 reference

12 December 2020

Use of atypical antipsychotics in refractory depression and anxiety.

1 reference

12 December 2020

One-year follow-up after successful ECT: a naturalistic study in depressed inpatients

1 reference

12 December 2020

Efficacy of modern antipsychotics in placebo-controlled trials in bipolar depression: a meta-analysis

1 reference

12 December 2020

Clinical guidelines for the treatment of depressive disorders. IV. Medications and other biological treatments.

1 reference

12 December 2020

The efficacy of drugs and psychotherapy in the treatment of acute depressive episodes

1 reference

12 December 2020

A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia

1 reference

12 December 2020

Neuropharmacological basis of combining antidepressants

1 reference

12 December 2020

[Symptoms and pathophysiological mechanisms of neuropathic pain syndromes]

1 reference

12 December 2020

STAR*D: what have we learned?

1 reference

12 December 2020

Recognition and diagnosis of atypical depression.

1 reference

12 December 2020

Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses

1 reference

12 December 2020

A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report

1 reference

12 December 2020

Does almost everybody suffer from a bipolar disorder?

1 reference

12 December 2020

The history and current state of antidepressant clinical trial design: a call to action for proof-of-concept studies

1 reference

12 December 2020

Developing treatment algorithms for unipolar depression in Cyberspace: International Psychopharmacology Algorithm Project (IPAP).

1 reference

12 December 2020

Comparison of the diagnosis of melancholic and atypical features according to DSM-IV and somatic syndrome according to ICD-10 in patients suffering from major depression

1 reference

12 December 2020

Efficacy and Safety of Combined ECT and Tricyclic Antidepressant Drugs in the Treatment of Depressed Geriatric Patients

1 reference

12 December 2020

Therapeutic use of sleep deprivation in depression

1 reference

12 December 2020

Do many patients with depression suffer from bipolar disorder?

1 reference

12 December 2020

Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study

1 reference

12 December 2020

New developments in the treatment of depression

1 reference

12 December 2020

Are tricyclic antidepressants useful for mild depression? A placebo controlled trial

1 reference

12 December 2020

International Consensus Group on the evidence-based pharmacologic treatment of bipolar I and II depression

1 reference

12 December 2020

Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain.

1 reference

12 December 2020

[Affective disorders. The significance of psychotherapeutic approaches]

1 reference

12 December 2020

Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatonin- agonist and selective 5HT2c receptors antagonist, in the treatment of major depressive disorders

1 reference

12 December 2020

Does early improvement in major depression protect against treatment emergent suicidal ideation?

1 reference

12 December 2020

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder

1 reference

12 December 2020

Mirtazapine compared with paroxetine in major depression

1 reference

12 December 2020

Predictors of therapeutic benefit from amitriptyline in mild depression: a general practice placebo-controlled trial

1 reference

12 December 2020

The Hamilton depression scale. Evaluation of objectivity using logistic models

1 reference

12 December 2020

Effectiveness of paroxetine in the treatment of acute major depression in adults: a systematic re-examination of published and unpublished data from randomized trials

1 reference

12 December 2020

Milnacipran versus other antidepressive agents for depression

1 reference

12 December 2020

Continuation therapy with lithium and amitriptyline in unipolar depressive illness: a randomized, double-blind, controlled trial

1 reference

12 December 2020

Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, double-blind, placebo-controlled st

1 reference

12 December 2020

Painful physical symptoms and treatment outcome in major depressive disorder: a STAR*D (Sequenced Treatment Alternatives to Relieve Depression) report.

1 reference

12 December 2020

Re-evaluating the prevalence of and diagnostic composition within the broad clinical spectrum of bipolar disorders

1 reference

12 December 2020

Augmentation treatment in major depressive disorder: focus on aripiprazole

1 reference

12 December 2020

Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression.

1 reference

12 December 2020

Agomelatine: The evidence for its place in the treatment of depression

1 reference

12 December 2020

STAR*D: revising conventional wisdom.

1 reference

12 December 2020

Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview

1 reference

12 December 2020

Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study.

1 reference

12 December 2020

Antidepressants and suicide: risk-benefit conundrums

1 reference

12 December 2020

Comparison of electroconvulsive therapy with imipramine in endogenous depression: a double blind study

1 reference

12 December 2020

Interpersonal psychotherapy and antidepressant medication: evaluation of a sequential treatment strategy in women with recurrent major depression

1 reference

12 December 2020

Double-blind comparison of addition of a second mood stabilizer versus an antidepressant to an initial mood stabilizer for treatment of patients with bipolar depression

1 reference

12 December 2020

Lithium augmentation of combined neuroleptic-tricyclic treatment in delusional depression

1 reference

12 December 2020

A comparative double-blind controlled study of trimipramine and amitriptyline in major depression: lack of correlation with 5-hydroxytryptamine reuptake blockade

1 reference

12 December 2020

Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report.

1 reference

12 December 2020

Treatment-resistant depression: definition and treatment approaches

1 reference

12 December 2020

Quetiapine monotherapy for bipolar depression

1 reference

12 December 2020

Sertraline versus other antidepressive agents for depression

1 reference

12 December 2020

Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons

1 reference

12 December 2020

Impact of antidepressant continuation after acute positive or partial treatment response for bipolar depression: a blinded, randomized study

1 reference

12 December 2020

Ranking antidepressants

1 reference

12 December 2020

Clinical and demographic features of atypical depression in outpatients with major depressive disorder: preliminary findings from STAR*D.

1 reference

12 December 2020

Parsing the clinical phenotype of depression: the need to integrate brief depressive episodes

1 reference

12 December 2020

The treatment of psychotic depression

1 reference

12 December 2020

Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study.

1 reference

12 December 2020

Combined psychotherapy and pharmacotherapy for depression. A systematic analysis of the evidence

1 reference

12 December 2020

Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers

1 reference

12 December 2020

Differential physiological effects of a low dose and high doses of venlafaxine in major depression

1 reference

12 December 2020

Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design.

1 reference

12 December 2020

Antidepressants for neuropathic pain

1 reference

12 December 2020

A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. Lamictal 602 Study Group.

1 reference

12 December 2020

Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches

1 reference

12 December 2020

A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression.

1 reference

12 December 2020

1 reference

12 December 2020

Should we expand the toolbox of psychiatric treatment methods to include Repetitive Transcranial Magnetic Stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders.

1 reference

12 December 2020

A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department

1 reference

12 December 2020

Australian and New Zealand clinical practice guidelines for the treatment of depression

1 reference

12 December 2020

A double-blind trial of bupropion versus desipramine for bipolar depression

1 reference

12 December 2020

A novel functional polymorphism within the promoter of the serotonin transporter gene: possible role in susceptibility to affective disorders

1 reference

12 December 2020

SSRIS versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability

1 reference

12 December 2020

Active placebos versus antidepressants for depression

1 reference

12 December 2020

Overview of psychiatric disorders and the role of newer antidepressants.

1 reference

12 December 2020

Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up

1 reference

12 December 2020

Amitriptyline for depression

1 reference

12 December 2020

Prediction of response to antidepressants: is quantitative EEG (QEEG) an alternative?

1 reference

12 December 2020

Amitriptyline versus other types of pharmacotherapy for depression

1 reference

12 December 2020

Diagnosing and treating patients with symptoms of depression

1 reference

12 December 2020

St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy

1 reference

12 December 2020

Is Catatonia a Primary Indication for ECT?

1 reference

12 December 2020

When at first you don't succeed: sequential strategies for antidepressant nonresponders

1 reference

12 December 2020

Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. Danish University Antidepressant Group

1 reference

12 December 2020

The clinical significance of antidepressant treatment effects cannot be derived from placebo-verum response differences

1 reference

12 December 2020

Long-term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study

1 reference

12 December 2020

Rate and predictors of prepubertal bipolarity during follow-up of 6- to 12-year-old depressed children

1 reference

12 December 2020

Antidepressants and the placebo response.

1 reference

12 December 2020

A double-blind, randomised, controlled clinical trial of acetyl-L-carnitine vs. amisulpride in the treatment of dysthymia

1 reference

12 December 2020

Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients.

1 reference

12 December 2020

Progress in the psychotherapy of mood disorders: studies from the Western Psychiatric Institute and Clinic

1 reference

12 December 2020

Time course of improvement under antidepressant treatment: a survival-analytical approach

1 reference

12 December 2020

Delayed onset of action of antidepressant drugs? Survey of recent results

1 reference

12 December 2020

Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.

1 reference

12 December 2020

A comparison of fluoxetine imipramine and placebo in patients with bipolar depressive disorder

1 reference

12 December 2020

Major depression: the importance of clinical characteristics and treatment response to prognosis

1 reference

12 December 2020

Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants

1 reference

12 December 2020

Algorithms for the treatment of subtypes of unipolar major depression

1 reference

12 December 2020

Lamotrigine in the treatment of recurrent brief depression

1 reference

12 December 2020

When do antidepressants worsen the course of bipolar disorder?

1 reference

12 December 2020

Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence.

1 reference

12 December 2020

The Relationship of Personality Disorders to Treatment Outcome in Depressed Outpatients

1 reference

12 December 2020

Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression

1 reference

12 December 2020

Augmentation strategies in the treatment of major depressive disorder. Examining the evidence on augmentation with atypical antipsychotics.

1 reference

12 December 2020

Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials.

1 reference

12 December 2020

Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries

1 reference

12 December 2020

Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms

1 reference

12 December 2020

Pilot study comparing in blind the therapeutic effect of two doses of agomelatine, melatoninergic agonist and selective 5HT2C receptors antagonist, in the treatment of major depressive disorders

1 reference

12 December 2020

Are psychological treatments for depression in primary care cost-effective?

1 reference

12 December 2020

Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo

1 reference

12 December 2020

Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data

1 reference

12 December 2020

Illuminating rationale and uses for light therapy.

1 reference

12 December 2020

Is the antidepressive effect of sleep deprivation stabilized by a three day phase advance of the sleep period? A pilot study

1 reference

12 December 2020

Subsyndromal depressive symptoms are associated with functional impairment in patients with bipolar disorder: results of a large, multisite study.

1 reference

12 December 2020

Current prescription patterns and safety profile of irreversible monoamine oxidase inhibitors: a population-based cohort study of older adults

1 reference

12 December 2020

Transcranial magnetic stimulation in the treatment of mood disorder: a review and comparison with electroconvulsive therapy

1 reference

12 December 2020

A proposed new approach to the clinical subclassification of depressive illness

1 reference

12 December 2020

Pharamacogenetics and antidepressant treatment in integrative psychiatry perspective.

1 reference

12 December 2020

A randomized trial comparing paroxetine and venlafaxine in the treatment of bipolar depressed patients taking mood stabilizers.

1 reference

12 December 2020

The angiotensin I converting enzyme insertion/deletion polymorphism influences therapeutic outcome in major depressed women, but not in men

1 reference

12 December 2020

Are benzodiazepines antidepressants?

1 reference

12 December 2020

Treatment of Major Depression With Psychotherapy or Psychotherapy-Pharmacotherapy Combinations

1 reference

12 December 2020

Fluoxetine versus other types of pharmacotherapy for depression

1 reference

12 December 2020

The definition and meaning of treatment-resistant depression

1 reference

12 December 2020

Escitalopram versus other antidepressive agents for depression

1 reference

12 December 2020

Phenelzine and amitriptyline in the treatment of depression. A comparison of present and past studies

1 reference

12 December 2020

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

1 reference

12 December 2020

Pharmacologic and therapeutic strategies in treatment-resistant depression. Switching antidepressants vs. conventional augmentation strategies

1 reference

12 December 2020

A comparison of phenelzine and imipramine in depressed inpatients

1 reference

12 December 2020

Differential outcome of bipolar patients receiving antidepressant monotherapy versus combination with an antimanic drug.

1 reference

12 December 2020

Bright-light therapy in the treatment of mood disorders

1 reference

12 December 2020

Lack of efficacy of fluoxetine in recurrent brief depression and suicidal attempts

1 reference

12 December 2020

Practice guideline for the treatment of patients with major depressive disorder (revision). American Psychiatric Association

1 reference

12 December 2020

Amoxapine versus amitriptyline combined with perphenazine in the treatment of psychotic depression

1 reference

12 December 2020

Effectiveness and feasibility of a standardized stepwise drug treatment regimen algorithm for inpatients with depressive disorders: results of a 2-year observational algorithm study

1 reference

12 December 2020

Update on quetiapine in the treatment of bipolar disorder: results from the BOLDER studies

1 reference

12 December 2020

A metaanalysis of clinical trials comparing moclobemide with selective serotonin reuptake inhibitors for the treatment of major depressive disorder

1 reference

12 December 2020

Response and remission criteria in major depression--a validation of current practice

1 reference

12 December 2020

"Difficult-to-treat depression"

1 reference

12 December 2020

1 reference

12 December 2020

Polymorphisms in the angiotensin-converting enzyme gene are associated with unipolar depression, ACE activity and hypercortisolism

1 reference

12 December 2020

Randomized, double-blind pilot trial comparing lamotrigine versus citalopram for the treatment of bipolar depression

1 reference

12 December 2020

A double-blind randomized comparison of nortriptyline plus perphenazine versus nortriptyline plus placebo in the treatment of psychotic depression in late life

1 reference

12 December 2020

New antidepressants in the treatment of neuropathic pain. A review.

1 reference

12 December 2020

Antidepressant treatment of the depressed patient with insomnia.

1 reference

12 December 2020

Are psychological and pharmacologic interventions equally effective in the treatment of adult depressive disorders? A meta-analysis of comparative studies.

1 reference

12 December 2020

Effectiveness of adjunctive antidepressant treatment for bipolar depression

1 reference

12 December 2020

Algorithms for optimizing the treatment of depression: making the right decision at the right time

1 reference

12 December 2020

Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis

1 reference

12 December 2020

Reevaluating therapies for bipolar depression.

1 reference

12 December 2020

Venlafaxine monotherapy in women with bipolar II and unipolar major depression

1 reference

12 December 2020

Short-term efficacy of tricyclic antidepressants revisited: a meta-analytic study

1 reference

12 December 2020

Brief dynamic therapy combined with pharmacotherapy in the treatment of major depressive disorder: long-term results

1 reference

12 December 2020

Modern Psychometrics in Clinimetrics: Impact on Clinical Trials of Antidepressants

1 reference

12 December 2020

Somatic symptoms, depression, and antidepressant treatment

1 reference

12 December 2020

Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.

1 reference

12 December 2020

A placebo-controlled comparison of lithium and triiodothyronine augmentation of tricyclic antidepressants in unipolar refractory depression

1 reference

12 December 2020

Evaluating antidepressant therapies: remission as the optimal outcome

1 reference

12 December 2020

Efficacy and safety of lamotrigine as add-on treatment to lithium in bipolar depression: a multicenter, double-blind, placebo-controlled trial

1 reference

12 December 2020

Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression

1 reference

12 December 2020

Rating scales in depression: limitations and pitfalls.

1 reference

12 December 2020

Are all antidepressants really the same? The case of fluoxetine: a systematic review.

1 reference

12 December 2020

Antidepressant-induced suicidality: an update.

1 reference

12 December 2020

Treatment of bipolar depression

1 reference

12 December 2020

Efficacy of milnacipran in patients with fibromyalgia.

1 reference

12 December 2020

Possible influence of the insertion/deletion polymorphism in the angiotensin I-converting enzyme gene on therapeutic outcome in affective disorders

1 reference

12 December 2020

Recurrent brief depression and personality traits in allergy, anxiety and premenstrual syndrome patients: a general practice survey

1 reference

12 December 2020

Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders. Report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination

1 reference

12 December 2020

Strategies and tactics in the treatment of chronic depression

1 reference

12 December 2020

[Predictive factors for therapeutic success in depressive syndrome]

1 reference

12 December 2020

Treating depression and pain

1 reference

12 December 2020

The effectiveness of lithium augmentation of milnacipran: preliminary data using the modified Japanese Psychopharmacology Algorithm

1 reference

12 December 2020

Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment?

1 reference

12 December 2020

The role of the serotonergic and noradrenergic neurotransmitter systems in the treatment of psychological and physical symptoms of depression

1 reference

12 December 2020

Sleep Deprivation and Circadian Rhythm in Depression

1 reference

12 December 2020

Definition and differential diagnosis of treatment-resistant depression

1 reference

12 December 2020